COVID19 Clinical Updates

 COVID-19 Clinical Updates

This event is ONLINE ONLY. You will receive a link to connect before each session date. Please Note: A recording of each webinar will be made available to the registrants post event. See below for details of the next webinar scheduled for June 9 – 12:00 noon.  This will be the last webinar in this series as we pause for the summer months. Please check back in the fall. Note: You only need to register ONCE – this is a series.

Overall Objectives

• Receive an update in the emerging pandemic of Corona virus-SARS2 utilizing short lectures, panel discussions and audience-speaker interaction
• Understand current evidence pertaining to the Corona virus-SARS2 epidemiology, pathogenicity of the virus, preventative and PPE use, public health management and response, therapeutic options, and pediatric considerations in management
• Be aware of reputable sources of appropriate evidence and information and guidelines for practice
• Recall the current messaging and guidance that healthcare providers need to pass onto their patients and the public pertaining to the emerging pandemic of Corona virus-SARS2

June 9, 2020 – 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – Vanessa Poliquin, MD, FRCSC – COVID-19 and Pregnancy: What we know and what we have yet to learn

By the end of this seminar the audience will:

• To be advised

1220-1240 – Joanne Embree, MD, FRCPC – COVID-19 from the pediatric perspective

By the end of this seminar the audience will:

• to be advised

1240-1300 – Q&A section

May 26, 2020 – 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – John Embil, MD, FRCPC – COVID questions that need answers

1220-1240 – Jared Bullard, MD, FRCPC Pediatrics, FRCPC Infectious Diseases – SARS-CoV-2: just how infective is this virus?

1240-1300 – Q&A section

May 12, 2020 – 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – Carl Boodman, MD – COVID-19 Therapeutic Management – a whilwind review of the evidence

By the end of this seminar the audience wil be more informed regarding:

• Evidence of investigational COVID-19 medications
• Essentials of supportive care
• What to do with regular medications

1220-1240 – Joss Reimer, MD, FRCPC, MPH – Public Health Measures – The numbers, testing and future plans

By the end of this seminar the audience will:

• Discuss the current epidemiology of COVID19 in Manitoba
• Review the testing strategy for Manitoba including plans for asymptomatic sentinel surveillance
• Describe the re-open strategy and future plans for increasing or decreasing public health restrictions

1240-1300 – Q&A section

April 28, 2020 – 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – Pierre Plourde – Novel Vaccines for COVID-19

By the end of this seminar the audience will:

• Outline novel immunization platforms under development for COVID19
• Describe DNA vaccines and novel vaccine delivery systems (electroporation, micro-needle arrays) and how they differ from traditional vaccines
• Describe advantages and disadvantages of new immunization platforms

1220-1240 – Simon Trepel – COVID and Kids

By the end of this seminar the audience will:

• To be advised soon

1240-1300 – Q&A section

April 14, 2020 – 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – Evelyn Lo, MD, FRCPC – PPE, what we know, what we don’t know and what is current

By the end of this seminar the audience will:

• Understand the importance of correct PPE usage to prevent exposure and spread of COVID19 infection
• Know which is the correct selection of PPE based on exposure risk
• Be able to explain the benefits of appropriate PPE use to patients and staff

1220-1240 – Santina Lee, MD, FRCPC – COVID-19 and Pediatric Considerations

By the end of this seminar the audience will:

• Recognise the symptomatology and illness severity amongst pediatric patients with COVID-19
• Evaluate the risk of transmission of SARS-CoV-2 on playgrounds and in the environment
• Understand the evidence on vertical transmission of SARS-CoV-2

1240-1300 – Q&A section

March 31, 2020, 1200-1300 hours – Virtual Seminar

Agenda

1200-1220 – Philippe Lagace-Wiens, MD, FRCPC, DTM&H: Diagnostics & Surveillance

By the end of this seminar the audience will:

• Understand the importance of correct test sampling technique to improve sensitivity and specificity
• Know how to interpret the types of tests available for Corona virus-SARS2
• Be able to correlate clinical symptoms with test results

1220-1240 – Yoav Keynan, MD, PhD: Therapeutics

By the end of this seminar the audience will:

• Recognise clinical symptoms of early and advanced disease from Corona virus-SARS2 (COVID19)
• Select the appropriate therapeutic choices for treatment of COVID19 infection
• Understand the risks associated with different options of medications for treatment of COVID19

1240-1300 – Q&A section

Study Credits

This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been approved by the CPD Medicine Program, University of Manitoba for up to 1.0 Mainpro+ credits per session.
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the CPD Medicine Program, University of Manitoba for a maximum of 1.0 hours per session.

Participants should only claim credit for the actual number of hours attended.
The University of Manitoba CPD Medicine Program is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME).

PROGRAM APPROVAL FOR CONTINUING EDUCATION (PACE)

This course may be of interest to dentists, dental hygienists, dental assistants and dental personnel.  It is now accredited for 1CE credit hour.  These activities have been planned and implemented in accordance with the standards of the Academy of General Dentistry Program. Approval for Continuing Education (PACE), Rady Faculty of Health Sciences, University of Manitoba Nationally Approved PACE Program Provider for FAGD/MAGD credit. Approval does not imply acceptance by any regulatory authority or AGD endorsement. The current term of approval extends from July 1, 2018 to June 30, 2022. Provider ID# 214210.

Other Resources

COVID -19 REPORTS
Reports from weekly report was produced by a collaboration of fellows, residents, medical students, faculty leads, and librarians from the University of Manitoba and the Medical Microbiology and Infectious Diseases community.

MB COVID-19 Report (03-21-2020)

MB-COVID-19-Report-03-27-2020